Related Experiment Video

Updated: Mar 7, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.2K

Development and validation of a prognostic model for acute-on-chronic hepatitis B liver failure

Fangyuan Gao1, Le Sun, Xieqiong Ye

  • 1aCenter of Integrative Medicine bStatistics Room, Beijing Ditan Hospital, Capital Medical University cDepartment of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.

European Journal of Gastroenterology & Hepatology
|February 15, 2017
PubMed

Insights

A new HINAT ACLF model accurately predicts short-term mortality in hepatitis B virus (HBV) acute-on-chronic liver failure (ACLF) patients. This model outperforms existing prognostic tools, offering improved prediction accuracy for HBV ACLF.

Area of Science:

  • Hepatology
  • Internal Medicine
  • Prognostic Modeling

Background:

  • Acute-on-chronic liver failure (ACLF) poses a significant mortality risk.
  • Existing prognostic models like CLIF-C ACLF have limitations in predicting outcomes for specific etiologies such as hepatitis B virus (HBV).
  • Accurate short-term mortality prediction is crucial for timely intervention in HBV ACLF patients.

Purpose of the Study:

  • To develop and validate a novel prognostic model for predicting short-term mortality in HBV ACLF.
  • To compare the performance of the new model against established prognostic scores.

Main Methods:

  • Retrospective and prospective cohorts of HBV ACLF patients were analyzed.
  • Univariate and multivariate Cox regression identified independent predictors of mortality.
  • A prognostic model (HINAT ACLF) was constructed using key risk factors.
  • Model performance was evaluated using receiver operating characteristic (ROC) curves and compared to existing scores.

Main Results:

  • The HINAT ACLF model incorporates hepatic encephalopathy, international normalized ratio, neutrophil-lymphocyte ratio, age, and total bilirubin.
  • The HINAT ACLF model demonstrated superior predictive accuracy compared to CLIF-C ACLF, MELD, and Child-Turcotte-Pugh scores.
  • Prediction error rates were reduced by 16.4-54.5% at 28 and 90 days post-ACLF diagnosis.

Conclusions:

  • The HINAT ACLF model accurately predicts short-term mortality in HBV ACLF patients.
  • This novel model offers improved prognostic capabilities for this specific patient population.
  • The HINAT ACLF model can aid in clinical decision-making and patient management.
Abstract

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
362